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Summary.-The Tennagen test has been evaluated in "normal" subjects, patients
with cancer (predominantly colorectal) and patients with non-malignant disease.
The incidence of positive values was found to be higher in patients with clinically
active cancer than in those with benign conditions or normal subjects. In our hands
the test fell far short of the 9000 reliability previously claimed. This may be partly
due to an underestimate of the upper normal limit in earlier studies.
A small series of follow-up studies after resection for colorectal cancer have so far
failed to reveal any advantage to be gained by Tennagen tests over existing methods,
but these studies will be continued.
CARCINOMA-EMBRYONIC antigen (CEA)
was first identified by Gold & Freedman
(1965) in colorectal tumours and to a
lesser extent in normal large bowel and
foetal tissue. It has since become clear
that this glycoprotein is present in other
tumours, and shows much heterogeneity
particularly in its carbohydrate constitu-
tion (Coligan et al., 1972; Banjo et al.,
1974).
Potter et al. (1978) identified a CEA-
related substance which they called JCL-
CEA, but after further characterization re-
named it Tennessee antigen or Tennagen.
In addition to the chemical characteristics
of this substance, a haemagglutination-
inhibition method of assay for human
serum was described and a wide range
of values in normal subjects, tumour-
bearing and non-tumour-bearing patients
was reported. The results indicated that
more than 9000of cancer patients gave
values in excess of 5.5 u/ml serum in the
test, including those with Dukes' Stage A
colorectal cancer. Conversely, little more
than 5% ofhealthy subjects gave similarlv
raised values, and 5-5 u/ml was therefore
taken as the upper limit of normal.
In a wide variety of non-malignant
conditions Tennagen was found to be
raised in a high proportion of patients,
but always falling substantially short of
9000. The Tennagen assay compared
favourably with the CEA radioimmuno-
assay in these authors' hands.
Further reports (Potter et al., 1979)
have evaluated the assay in terms of
initial diagnosis, staging and serial moni-
toring. It was concluded that the assay
was valuable not only in diagnosis but
also in monitoring recurrence after surgical
removal or other therapy. A recent
report (Oehr et al., 1981) has evaluated
Tennagen, CEA and Tissue Polypeptide
Antigen in patients with bladder or
testes cancer, where each antigen was
found to be raised in 5000 of cases
regardless of stage, but no controls were
included. The subject is reviewed in
detail by Seidenberger (1980).
We report here a preliminary evaluation
of the test as a general test for cancer in
"normal" subjects, patients with non-
malignant diseases and patients with
various histologically confirmed cancers.
In a group of patients with colorectal
cancer, serial testing in parallel with
radioimmunoassay estimations for CEAC. R. PENTYCROSS
was performed. The times chosen for
assaying Tennagen were made to coincide
with those selected by our clinical col-
leagues for routinely assaying CEA, which
obviated unnecessary venepunctures.
MATERIALS
The reagents for the Tennagen test were
supplied by the Boehringer Corporation
(U.K.) and included "Lancer Directions
Manual". Tennagen Indicator Cells, Anti-
Tennessee Antigen serum, Tennagen Standard
Extract, Tennagen Extract-Normal level,
Tennagen diluent, Microtitre "U" plates,
Microtitre dilutors, Microtitre pipettee drop-
pers, Go-No-Go tester, sealing tape, Micro-
titre reading mirror, Tennagen human serum
control kit (3 levels) and dialysis tubing
(Union Carbide).
Additional items were Terumo micro-
syringe (Terumo Corporation, Tokyo) and
1-1M perchloric acid (Analar grade, B.D.H.
Ltd, Poole).
SUBJECTS
The "normal" subjects used in this study
were drawn from the staff of the Charing
Cross Hospital and other volunteers. Care
was taken to exclude staffinanywayinvolved
with cancer patients or who handled tumour
material. Previous experience in this labora-
tory with other tests (Browne et al., 1980)
has shown this to be a necessary precaution.
Nevertheless the word '"normal" is not
strictly accurate when discussing the healthy
volunteers tested in this study, although
5/22 were not hospital staff. The patients
were attending Charing Cross Hospital,
St Mark's Hospital, London, Birmingham
General Hospital and Llandudno General
Hospital, Wales. The sex, age and diagnosis
ofthe groups studied are indicated in Table I.
For the purpose ofthis test cancer patients
were grouped as "active" with clinical or
radiological evidence of disease or a "clinical
remission" with no clinical or radiological
evidence ofdisease.
Staging of patients with colorectal cancer
was based on clinical, radiological and
laparotomy evidence. Blood samples for
assessment in relation to disease stage
according to Dukes' criteria (1937), were
obtained on the day staging was ascertained.
METHODS
The method as described in the "Lancer
Directions Manual" was followed with
scrupulous care.
Blood (5-10 ml) was obtained by vene-
puncture and transferred from the syringe
to a glass container, allowed to clot, centri-
fuged and the serum transferred to a sterile
glass bijou bottle for storage at -20°C.
Where blood had been taken in other centres,
it was ascertained that this procedure had
been followed. For extraction, 1 0 ml ofserum
was thawed at room temperature and
TABLE I.-Tennessee antigen test: Breakdown of each clinical group by sex and age
Sex
M F
Normal subjects 6 16
Patients with non-malignant diseases* 16 13
Cancer patients
Colorectal 37 30
Pancreas 2 4
Oesophagus 2 2
Stomach 7 2
Lung 2 3
Ovary - 3
Breast - 6
Testist 4
Other: 6 6
Age range
18-55
25-72
48-88
51-75
54-79
53-76
52-80
55-79
39-54
23-66
34-75
Mean
27-2
49-8
67-6
62-6
62-5
60-3
63-7
64-7
45-3
42-2
52-8
*Diagnosed as follows: ulcerative colitis2; diverticultis 1; irritable colon 2; peptic ulcer 7; haemorrhoids 6;
cirrhosis and cholelithiasis 4; chronic pancreatitis 2; and 1 each with hyperthyroidism, coronary artery
bypass, pelvic abscess, anal tags and colonic polyp.
tMalignant teratoma, 1 ofwhom also had seminoma.
tFive with adenocarcinoma or undifferentiated carcinoma of unknown origin, 2 patients with noll-
Hodgkin's lymphoma and 1 each with the following: Hodgkin's disease, chondrosarcoma, invasive mole,
anal squamous-cell carcinoma, and ca, Ampulla of Vater.
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pipetted into a glass tube, followed by 1 0 ml
of perchloric acid and thoroughly mixed for
30 min. The mixture was centrifuged at
2000g for 10 min.
The supernatant was transferred to dialysis
tubing which had been pre-soaked in distilled
water, and was dialysed overnight against
distilled water. The dialysed extract was then
aliquoted into 3 portions of 0-3 ml each for
freezing at -20°C. Sometimes the size
of the original blood sample necessitated
preparing less than 10 ml serum (and
correspondingly less perchloric acid used in
the extraction). In these circumstances the
final aliquots would be smaller.
Important points in the performance ofthe
test included:
1. Checking the microdilutors for proper
delivery of 25 ul on a "Go-No-Go" pad
before making the serial dilutions; also
flaming the tips after each experiment.
2. Stringent avoidance of even minimal
vibration ordisturbance whiletheplate was
in position.
3. Re-reading the tests at intervals for a
period of 3-4 h to assess stability. If
unstable, the test was regarded as invalid.
4. The test was regarded as invalid if the 3
control sera were not within the limit
indicated in the test kit. The limits given
are: Level I (2-7 u/ml), Level II (3-9-7-7
u/ml) and Level III (10-9-15-5 u/ml).
It was decided that the test should be
invalidated if even one control result fell
outside the required limits. This only
happened on 3 occasions during the course
of the study and could be attributed to
vibration each time.
Tennagen values are quoted as u/ml.
Values over5-5u/mlwereregardedaspositive.
CEA was measured by double-antibody
radioimmunoassay (Searle et al., 1974) and
values up to 10ng/ml were obtained innormal
subjects or non-malignant disease.
RESULTS
Tests were performed on 22 normal
subjects, 29 patients with various non-
malignant diseases and 116 patients with
a histological diagnosis of cancer.
The instruction manual stated that the
frozen dialysed extract could be thawed
and frozen repeatedly without affecting
the results. Since it is sometimes necessary
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FIG. 1.-Second test (twice-thawed aliquot) result
expressed as % of first test result, according to
time of storage at -20°C.
to repeat tests we decided to evaluate
this claim. Accordingly we set up repeat
tests at varying intervals after the first
test, using the previously tested (and
hence twice thawed) aliquot and an
"undisturbed" aliquot. Fig. 1 shows that
regardless of the period during which
the extracted samples were frozen, the
twice-thawed aliquot frequently showed
a drop in Tennagen values at the second
test. On one occasion, inexplicably, it
showed a rise. The once-frozen aliquots
invariably gave identical values to those
found in the first test with the first
aliquot. The tests were run in duplicate
where availability ofthe extracted samples
permitted. On no occasion was there any
disparity between duplicate results.
Our experience with the technique
suggests that readings should be taken
after 60 min, though they remain stable
for several hours afterwards. On two
occasions we found no change after
incubation overnight.
Fig. 2 indicates the Tennagen values
in the sera of "normal" individuals,
TABLE II.-Stati8tical evaluation between
4 groups
Other groups P
A V8 B <0-01
A V8 C <0-01
A V8 D <0-002
B V8 C >0 05
B V8 D <0-05
C V8 D >0-05
A="normal" individuals; B=patients with non-
malignant conditions; C =patients with colorectal
cancer in clinical and radiological remission;
D =patients with clinically active colorectal cancer.
.-
225C. R. PENTYCROSS
21.9
E~15.4
1.
CL
C. 10.9 !o9
I ,.,
K
.0
*-hM3.O.9 ewe,
a_
__S
0
so so 0
x
x
. I-
i- - 1-4- I-- - Iss 1 mm -- mm 9 _ I_ _ - | 315,'t --- ----l------T-----l----- 3.91 0
2.71-1S
L.9[ x sa
2-bL pan.
Ca
cob-
rfectum
ca Ca ia Ca Msc Mi
stoachoseoph. lung bra canoers non-
cancers
FIG. 2.-Distribution ofTennagen titres for various groups of cancer patient, "normal" subjects and patients
with non-malignant conditions. The miscellaneous group includes patients classified in Table I as ovary,
testis and other cancers ( x, clinically and radiologically tumour free; 0, clinically or radiologically
evident disease).
TABLE III.-Tennessee antigen test: Comparison of pre- and post-operative (8 days)
serum levels of Tennagen (u/ml) and CEA (ng/ml) in patients with surgery for
colo-rectal carcinoma
Tennagen
(-~~~~~~~~~~~~~
Patient
J.C.
B.Y.
B.J.
T.S.
F.B.
R.B.
L.B.
W.S.
Pre-op
5.5
15-4 5.5
15-4
5-5
7.7
7.7
5-5
Post-op
10-9
10-9
21 *9
21 *9
2-7
10-9
15-5
10-9
CEA
r~~~~~~~~~~~~~~~~~~~~~'
Pre-op
110
ND
<2
29
2
<2
<2
5
Post-op
69
ND
<2
43
3
4
<1
<2
Dukes
C
D
A
D
B
A
C
B
subjects with non-malignant conditions
and patients with evident cancer or in
clinicalremission. Themiscellaneous cancer
group included 3 ovarian cancers and 4
testical tumours listed in Table 1. Results
in patients with colorectal carcinoma
classified in accordance with Dukes'
staging are shown in Fig. 3.
A statistical analysis of the com-
parisons between 4 groups is given in
Table II, using the Wilcoxon Rank Sum
Test.
Fig. 4 shows studies in respect of
Tennagen and CEA in a group of patients
with colorectal cancer before and after
primary resection of their tumours. Pre-
operative and post-operative 8th day
samples were assayed, and in some cases,
monthly samples thereafter. Two of 5
patients had a higher Tennagen value
226
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compared with 3/6 with higher CEA
value pre-operatively.
Table III summarizes the pre-operative
and post-operative 8th day values for
both markers in 5 of the 6 patients and
3 others. In 4 patients there was an
increase in the Tennagen values in the
8th day sample, not accompanied by a
rise in CEA. In 2 patients both markers
showed a rise, in 1 there was no rise in
either marker and in another there is no
CEA result for comparison.
Fig. 5 indicates monthly follow-up
studies in 6 patients in remission after
previous resection of colorectal cancer.
One of the 6 patients showed rising values
of both Tennagen and CEA, which were
concurrent with clinically evident pro-
gression of the disease, going on to deathi.
DISCUSSION
The observations reported here indicate
that repeated freezing and thawing of
the extracts does, contrary to the instruc-
tions provided, modify the results ob-
tained and must be avoided to achieve
reproducible results. However, the storage
time does not have a statistically signi-
ficant effect on the changes noted. Repro-
ducibility of the test on once-frozen
aliquots proved to be very consistent,
and long storage is compatible with
--I
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pre-op Post-operative period
Fia. 4. Follow-up studies Onl colorectal cancer patients including pre-operative an(l 8 days post-operatiVe
(thereafter 4-weekly) ( CEA, -- - Tennagen).
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FIa. 5.-Follow-up studies at 4-weekly intervals on colorectal cancer patients (Pre-operative and 8 days
post-operative samples). In the abscissa, each interval between numerals represents 4 weeks (- CEA,
- -- Tennagen).
reproducible results. Since it is sometimes
necessary to repeat a test, these con-
siderations are important.
Our results indicate that the normal
upper limit of5 5 u/ml is open to question
since 5/22 "normal" subjects and 17 of 29
patients with non-malignant disorders
had values over 5.5 u/ml. Increasing the
"normal" range to 7-7 u/ml reduced the
incidence of false-positive results in these
two groups to 2/22 and 11/29 respectively.
As regards the "normal" group the revised
upper limit of normal gives a percentage
ofpathological results only slightly higher
than in previously published work, and
would seem to justify taking 7'7 u/ml
as the upper limit ofnormal.
This does not hold forthenon-malignant
disease group. Furthermore, taking the
upper limit ofnormal as 5 5, the incidence
of positive results in patients with
clinically evident cancer was 46/65 and
with the limit raised to 7 7, the figure
was only 25/65. It would thus appear
that the ability of the Tennagen test in
its present form to discriminate between
cancer and other diseases is low. It should
also be noted from the statistical data
in Table II that the colorectal-cancer
patients in clinical remission did not
differ significantly from those with clini-
cally active disease, nor from those having
non-malignant conditions. Also it is a
limitation of the test that the results,
in arbitrary units, are necessarily ex-
pressed in a stepwise manner.
This low sensitivity of the test may
be explained by our finding (see Table III)
in 3/8 cases of colorectal cancer, that
whereas the pre-operative serum level of
Tennagen was within the previously
prescribed upper normal limit of 5-5 u/ml,
the post-operative 8th day sample had a
raised level. In 3 further patients the
pre-operative level was raised but the
post-operative value was higher still.
It seems possible that surgical manipula-
tions caused a release of antigen into the
blood.
It remains to be determined whether
surgery for non-malignant disease pro-
duces a transient increase in Tennagen
values, but clearly the interval between
surgery and sampling for Tennagen values
can affect the results.
In this small series of follow-up studies
there has been only one clinical relapse.
There was a rise in both Tennagen and
CEA values at the time of relapse and
both values rose in parallel before death.
This patient (N.M. in Fig. 5) had ad-
vanced metastatic disease and was there-
E
z 2
E uJ
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fore in Dukes' D classification. This
Figure shows rises in Tennagen in 2 other
patients, M.M. and D.D., not accompanied
by a rise in CEA values. In a further
patient (J.T.) the rise in Tennagen was
out of phase with that in CEA. It should
be noted in this context that Potter et al.
(1978) found somewhat raised values in
patients with non-malignant disorders,
which raises the possibility of Tennagen
being an inflammatory rather than a
neoplastic antigen. It may be relevant
that patient M.M. had some inflammatory
problems, with a bowel colostomy 1 week
before her transient rise in Tennagen.
On this small series it would be premature
to evaluate the Tennagen assay as a
means for monitoring disease progress.
Further study of this monitoring applica-
tion is needed.
Our percentage of raised values in
benign disorders is considerably more
than published values, and in malignant
disease, considerably less, so in our hands
the specificity of the Tennagen test, as at
present constituted, appears to fall below
the level for optimal clinical utility as a
general test for cancer.
The author is indebted to the clinicians who
allowed their patients to be used in this study
the "normal" healthy volunteers who gave blood,
Mr J. Towse and Mr G. Ward of the Boehringer
Corporation for reagents and Professor K. D.
Bagshawe for helpful advice and criticism.
This work was supported by a grant from the
Cancer Research Campaign.
REFERENCES
BANJO, C., SHUSTER, J. & GOLD, P. (1974) Inter-
molecular heterogeneity of the carcino-embryo-
nic antigen. Cancer Res., 34, 2114.
BROWNE, P., ABXL, E. W. & PENTYCROSS, C. R.
(1980) The leukocyte adherence inhibition test:
A study on three groups of cancer patients.
Tumor Diagnostik, 1, 266.
COLIGAN, J. E., LAUTENSCHLEGER, J., EGAN, M.
& TODD, C. (1972) Isolation characterization of
carcinoembryonic antigens. Immunochemi8try, 9, 1.
DUKES, C. E. (1937) Histological grading of rectal
carcinoma. Proc. R. Soc. Med., 30, 371.
GOLD, P. & FREEDMAN, S. (1965) Demonstration of
tumour-specific antigens in human colonic car-
cinomata by immunological tolerance and absorp-
tion techniques. J. Exp. Med., 121, 439.
OEHR, P., ADOLPHS, H-D., WUSTROw, A., KLAR, R.,
SCHLOSSER, T. & WINKLER, C. (1981) Simultan-
bestimmung von CEA, TAG and TPA in Serum
von Harnblasencarcinom-Patienten. Analyse von
Markerfrequenz und Markerunabhangigkeit unter
Berucksichtigung von Tumorstadium, Maligni-
taitsgrad und Krankheitsverlauf. Tumor Diagno8-
tik, 2, 27.
POTTER, T. P., JR, JORDAN, T., JORDAN, J. D. &
LASATER, H. (1978) Tennessee antigen (Tennagen):
Characterization and immunoassay of a tumour
associated antigen. In Prevention and Detection
of Cancer, Part 2 (Ed. Nieburgs). New York:
Marcel Dekker Inc. p. 467.
POTTER, T. P., JR, JORDAN, J. D-.- & JORDAN, T. A.
(1979) Compendium of A8s,ay8 for Immuno-
diagno8i8 of Human Cancer (Ed. Herberman).
Amsterdam: Elsevier North-Holland. p. 217.
SEARLE, F., LOVESEY, A. C., ROBERTS, B. A.,
ROGERS, G. T. & BAGSHAWE, K. D. (1974)
Radioimmunoassay methods for carcinoembryonic
antigen. J. Immunol. Methods. 4, 113.
SEIDENBERGER, H. B. (1980) Das Tennessee Antigen,
ein neues tumorassoziiertes Antigen. Tumor
Diagno8tik, 1, 45.
16